Brief: Karolinska Development's Portfolio Company Initiates Clinical Phase 1 Program With PN-6047

Kdventures AB

19/08/2022 07:43

Aug 19 (Reuters) - Karolinska Development AB  KDEV.ST :
    * PORTFOLIO COMPANY PHARMNOVO HAS INITIATED CLINICAL PHASE 1
PROGRAM WITH PN-6047, A CANDIDATE DRUG DEVELOPED AS A POTENTIAL
TREATMENT OF NERVE PAIN
    * CLINICAL PHASE 1 PROGRAM IS CARRIED OUT IN COLLABORATION
WITH
CTC IN UPPSALA AND IS EXPECTED TO LAST UNTIL MIDDLE OF 2023

Source text for Eikon:  ID:nGNE56r0pP 
Further company coverage:  KDEV.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))